Fto-flox Mouse
一般名
Fto-flox
製品ID
S-CKO-09550
背景情報
C57BL/6NCya
系統ID
CKOCMP-26383-Fto-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Fto-flox Mouse(カタログ番号S-CKO-09550)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Fto-flox
系統ID
CKOCMP-26383-Fto-B6N-VA
遺伝子名
製品ID
S-CKO-09550
遺伝子別名
mKIAA1752
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conditional knockout
染色体
Chr 8
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000069718
NCBIトランスクリプトID
NM_011936
ターゲット領域
Exon 3
有効領域の大きさ
~1.5 kb
遺伝子研究の概要
Fto, short for fat mass and obesity associated protein, is the first reported RNA N6 -methyladenosine (m6A) demethylase in eukaryotic cells. m6A is a prevalent mRNA internal modification that impacts cellular processes such as alternative splicing, stability, and expression. Fto has been associated with various biological processes, including adipogenesis, nutrient sensing, regulation of mRNA translation, and general growth [1,2].
Genome-wide association studies (GWAS) have linked single-nucleotide polymorphisms (SNPs) within Fto to obesity, as well as multiple cancers like endometrial, breast, pancreatic, and melanoma [1]. In diabetes-induced vascular endothelial dysfunction, enhanced Fto reduces global m6A levels in hyperglycemia, and Fto knockdown in endothelial cells leads to less inflammation and compromised migration and tube formation abilities. EC-specific Fto-deficient (EC FtoΔ/Δ) diabetic mice show less retinal vascular leakage and acellular capillary formation, suggesting the Fto-TNIP1-NF-κB network could be a potential target for treating diabetic vascular complications [3]. In osteoporosis, variation in Fto disturbs m6A methylation in RNAs, regulating cell proliferation, differentiation, and apoptosis. Pharmacological inhibition of Fto affects bone mass, bone mineral density, and adipose tissue distribution, indicating Fto-targeting small molecules could be novel osteoporosis treatments [4]. In multiple myeloma, up-regulation of Fto leads to decreased m6A methylation in plasma cells, and Fto promotes tumor-promoting and pro-metastatic functions by post-transcriptionally activating HSF1 in an m6A-YTHDF2-dependent manner. Inhibition of Fto, especially combined with bortezomib, synergistically inhibits myeloma bone tumor formation and extramedullary spread [5].
In conclusion, Fto, as an m6A demethylase, plays crucial roles in multiple biological processes and diseases. Studies using gene knockout or conditional knockout mouse models, like the EC FtoΔ/Δ mice in diabetes-related vascular complications, have been instrumental in revealing Fto's functions. These findings in model-based research highlight Fto's significance in obesity, diabetes-related vascular diseases, osteoporosis, and multiple myeloma, providing potential therapeutic targets for these conditions.
References:
1. Azzam, Sarah Kassem, Alsafar, Habiba, Sajini, Abdulrahim A. 2022. FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. In International journal of molecular sciences, 23, . doi:10.3390/ijms23073800. https://pubmed.ncbi.nlm.nih.gov/35409166/
2. Loos, Ruth J F, Yeo, Giles S H. 2013. The bigger picture of FTO: the first GWAS-identified obesity gene. In Nature reviews. Endocrinology, 10, 51-61. doi:10.1038/nrendo.2013.227. https://pubmed.ncbi.nlm.nih.gov/24247219/
3. Zhou, Chuandi, She, Xinping, Gu, Chufeng, Chen, Haibing, Zheng, Zhi. 2023. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1. In The Journal of clinical investigation, 133, . doi:10.1172/JCI160517. https://pubmed.ncbi.nlm.nih.gov/37781923/
4. Huang, Mei, Guo, Jianmin, Liu, Lifei, Chen, Xi, Zou, Jun. 2023. m6A demethylase FTO and osteoporosis: potential therapeutic interventions. In Frontiers in cell and developmental biology, 11, 1275475. doi:10.3389/fcell.2023.1275475. https://pubmed.ncbi.nlm.nih.gov/38020896/
5. Xu, Aoshuang, Zhang, Jiasi, Zuo, Liping, Sun, Chunyan, Hu, Yu. 2021. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. In Molecular therapy : the journal of the American Society of Gene Therapy, 30, 1104-1118. doi:10.1016/j.ymthe.2021.12.012. https://pubmed.ncbi.nlm.nih.gov/34915192/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
